Larotrectinib (also named as LOXO-101, ARRY-470) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRKA,TRKB and TRKC) family receptors. It is specifically developed for the treatment of TRK-Fusion cancers.
Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence. 
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. 
 B.Ricciuti, et al, Med. Oncol., 2017, 34(6), p 105.
 A.Drilon, et al, N. Engl. J. Med., 2018, 378(8), pp 731-739.
NONH for all modes of transport
Sales limitations may apply.
1. Product Specification
2. Safety Data Sheet
Please inquire for pricing and availability of this product by writing email firstname.lastname@example.org.